Activation of TLR9 by subcutaneous injection of agonistic CpG-containing double-stranded DNA (dsDNA) prevents the development of dextran sodium sulfate (DSS)-induced colitis in a type I IFN-dependent manner when TLR9 agonists were administered before colitis induction [8,9]. The gene discussed is TLR9; the disease is colitis.